Related Experiment Video
Updated: Feb 17, 2026
11:47
A Novel in vivo Gene Transfer Technique and in vitro Cell Based Assays for the Study of Bone Loss in Musculoskeletal Disorders
Published on: June 8, 2014
12.2K
Zoledronic acid in pediatric metabolic bone disorders
Sasigarn A Bowden1, John D Mahan2
1Division of Endocrinology, Department of Pediatrics, Nationwide Children's Hospital/the Ohio State University College of Medicine, Columbus, Ohio, USA.
Translational Pediatrics
|November 30, 2017
Summary
Zoledronic acid (ZA), a potent bisphosphonate, offers convenient treatment for pediatric osteoporosis and other bone disorders. This review details its pharmacology, efficacy, and safety in children.
Area of Science:
- Pediatric Endocrinology
- Pediatric Rheumatology
- Pediatric Oncology
Background:
- Zoledronic acid (ZA) is a potent intravenous bisphosphonate (BP) increasingly used in pediatric patients.
- Its convenience in infusion time and dosing frequency makes it favorable compared to pamidronate.
- ZA shows efficacy in various conditions including osteoporosis, hypercalcemia, fibrous dysplasia, and bone metastases.
Purpose of the Study:
- To review the pharmacologic properties, mechanism of action, and dosing of ZA in pediatric metabolic bone disorders.
- To summarize therapeutic outcomes and discuss novel applications of ZA in children.
- To highlight safety concerns and adverse effects associated with ZA use in pediatric populations.
Main Methods:
- Literature review of studies on zoledronic acid in pediatric bone disorders.
- Analysis of pharmacologic data, clinical trial results, and case reports.
- Synthesis of information on efficacy, safety, and dosing regimens.
Main Results:
- ZA is effective for primary and secondary osteoporosis in children.
- Beneficial effects observed in hypercalcemia of malignancy, fibrous dysplasia, and osteonecrosis.
- ZA offers advantages in administration compared to older bisphosphonates.
Conclusions:
- Zoledronic acid is a valuable therapeutic option for various metabolic bone disorders in children.
- Further research into novel uses and long-term safety is warranted.
- Careful consideration of safety and adverse effects is crucial for optimal patient management.
Related Concept Videos
01:24Pharmacokinetics in Pediatric Patients: Drug Metabolism
257
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
257
01:29Bone Disorders
5.6K
Aging and its effect on bone remodeling is the most common cause of bone disorders. In young and healthy people, bone deposition and resorption happen at an equal rate to maintain optimal bone health.
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...
5.6K
01:17Pharmacokinetics in Pediatric Patients: Drug Distribution
337
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
337
01:26Pharmacokinetics in Pediatric Patients: Drug Excretion
284
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
284
01:23Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
324
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
324
01:31Osteoclasts in Bone Remodeling
4.3K
Osteoclasts are cells responsible for bone resorption and remodeling. They originate from hematopoietic progenitor cells present in the bone marrow. Numerous progenitor cells fuse to form multinucleated cells, each with 10-20 nuclei. A single osteoclast has a diameter of 150 to 200 µM. These cells have ruffled borders that break down the underlying bone tissue and release minerals such as calcium into the blood in bone resorption. Osteoclasts cling to bones with their ruffled edges during...
4.3K